COMy 2026 | How may the subcutaneous OBI version of isatuximab impact the QoL of patients with MM?

Isatuximab is an incredible anti-CD38 monoclonal antibody that is currently the backbone in frontline setting according to isatuximab-VRd IMROS combination. Exciting results in terms of deepness of response, MRD rate, and in some way at the long-term potential cure for our elderly patients. Let’s not forget the data from GMMG HD7 in transplant-eligible settings, also front-line, and in isa-Kd, isatuximab carfilzomib dexamethasone, and isa-pom-dex in relapsed/refractory settings. IRAKLIA was an incredible clinical trial in which we have determined the non-inferiority of isatuximab performed in subcutaneously versus isatuximab intravenously. This was an isa-pom-dex combination. There is another trial, IZALCO, in which the same study was performed with Isa-Kd. However, the subcutaneous administration of isatuximab was performed through OBI. That is a small button that we apply on the abdomen of our patient that in a really safe and tolerable way permits to administer in a correct way isatuximab inside our patients. And this is something that correlates with an incredible satisfaction from the patient, from the caregiver, but also, let’s not forget, from hospital staff, because this is really safe and simple to administer. And inside the IRAKLIA trial, there was also a cohort of patients that had this opportunity to perform OBI injection in their domestic setting. So we had the opportunity to deliver anti-CD38 antibody at home. And this is something unique. And I have to say, patients are absolutely excited to continue to live their lives, not moving to the hospital. So this impact in an incredible way on quality of life. Inside the clinical trials, we have seen evaluations from tolerability, efficacy, and also patients’ reported outcomes. Everyone confirmed that together with OBI, isatuximab could become more and more the standard of care, particularly in frontline setting, because I think that the idea to not touch the skin of our patients is the next future. The idea to not only care about the effectiveness of the treatment, but the idea of thinking to the patient in the 360 degrees. The idea to really impact on their lives and the idea to not give pain to the patients for every procedure that we do. OBI is going to be approved everywhere, now has EU approval, and I think that we will see as soon as possible in our current daily practice and I really look forward to it because this is a really impactful novelty for our patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.